Tesamorelin vs retatrutide: evidence, cost, and legality

Which is better, tesamorelin or retatrutide?

On access and regulatory status tesamorelin wins: it is approved and available by prescription as Egrifta WR, while retatrutide is not approved anywhere and cannot be compounded. On the size of the effect retatrutide's trial results are far larger, for both body weight and liver fat, but they come from phase 2 and early phase 3 trials with no cardiovascular outcomes data. For obesity, the lawful comparison for retatrutide is an approved GLP-1 medicine, not tesamorelin, whose only approved use is HIV associated abdominal fat. [1] [4] [5] [7] [8] [10] [12]

How do tesamorelin and retatrutide compare?

Tesamorelin and Retatrutide compared by dimension
Dimension	Tesamorelin	Retatrutide
Mechanism [4] [8]	Stabilized 44 amino acid GHRH analog: raises the body's own growth hormone and IGF-1, which mobilizes visceral fat.	Single peptide that activates the GIP, GLP-1, and glucagon receptors: lowers appetite, slows gastric emptying, and raises energy expenditure.
What the trials measured [1] [4]	Visceral fat by CT scan. Pooled phase 3 trials in 806 adults with HIV: minus 24 versus plus 2 cm2 at 26 weeks (treatment effect minus 15.4%), with no change in abdominal fat under the skin.	Total body weight. Phase 2 trial in 338 adults with obesity: minus 8.7%, 17.1%, 22.8%, and 24.2% at 1, 4, 8, and 12 mg versus minus 2.1% on placebo at 48 weeks.
Note: Different outcomes, populations, and trial lengths. No direct comparison exists.
People without HIV [2] [6]	One 12 month trial in 60 abdominally obese adults with reduced GH secretion: visceral fat treatment effect minus 35 cm2, with lower triglycerides and no change in glucose or HbA1c.	Trials enrolled adults with obesity or type 2 diabetes; the phase 3 TRANSCEND-T2D-1 trial (537 adults, 40 weeks) improved glycemic control and weight versus placebo.
Liver fat [3] [5]	HIV with fatty liver (61 adults, 12 months): hepatic fat fraction down an absolute 4.1%; 35% versus 4% on placebo reached normal liver fat.	Substudy of 98 adults with fatty liver: relative liver fat change at 24 weeks of minus 82.4% at 12 mg versus plus 0.3% on placebo; 86% versus 0% reached normal liver fat.
FDA status [7] [8]	FDA approved: Egrifta (2010), Egrifta SV (2019), and Egrifta WR, for excess abdominal fat in adults with HIV and lipodystrophy.	Not approved by FDA or any other regulator. Phase 3 obesity trials (TRIUMPH) are the confirmatory step.
Compounding status [10] [11] [12]	Biologic since March 2020 (BLA 022505), so it is not eligible for 503A or 503B compounding; Egrifta WR by prescription is the only lawful product. Fat loss in people without HIV is off label.	Not a component of an approved drug and not on the 503A bulks list, so it cannot lawfully be compounded. The only lawful access is a registered clinical trial.
Dosing [1] [7] [8]	Egrifta WR label: 1.28 mg injected under the skin of the abdomen once daily; the effect fades after stopping.	No approved dose. Weekly injections have been given only inside clinical trials.
Side effects [4] [8]	Arthralgia (about 13%), injection site reactions, peripheral edema, myalgia, paresthesia; the label advises monitoring glucose and IGF-1.	Dose related nausea, diarrhea, vomiting, and constipation, mostly mild to moderate, and a dose dependent heart rate rise that peaked at 24 weeks; long term safety not established.
WADA status [13]	Prohibited at all times under section S2 (GHRH analogues).	Prohibited at all times under section S0 (non-approved substances).
Typical cost [9] [12]	Egrifta WR retail cash price about 10,709 USD per 28 day kit at a listing checked 2026-09-22; plans cover it for the HIV indication, usually with prior authorization.	No lawful price. Trial participants receive it at no cost; products sold online as retatrutide are unapproved and unverified.
Note: Prices at the verification date change often.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Tesamorelin and Retatrutide: grade, status, and cost
Attribute	Tesamorelin	Retatrutide
Class	Synthetic 44 amino acid analog of human growth hormone releasing hormone with an N-terminal trans-3-hexenoic acid modification that resists enzymatic degradation	Investigational triple agonist of the GIP, GLP-1, and glucagon receptors (single acylated peptide, once weekly)
What it is	FDA approved lab-made growth hormone releasing hormone (Egrifta, 2010) that cuts deep belly fat about 15% in HIV lipodystrophy and cut liver fat in a trial.	Investigational triple agonist, nicknamed reta or GLP-3, with 24.2% weight loss at 48 weeks in phase 2 and 28.3% in a phase 3 topline; not FDA approved.
Evidence	Evidence: Human RCT evidence	Evidence: Human RCT evidence
FDA status	Regulatory: FDA approved	Regulatory: Not eligible for compounding
Compounding	FDA approved as Egrifta (tesamorelin for injection) on November 10, 2010, for reduction of excess abdominal fat in HIV infected adults with lipodystrophy; Egrifta SV, a 2 mg vial formulation, was approved in 2019, and Egrifta WR, an 11.6 mg vial formulation, in March 2025. Tesamorelin is a 44 amino acid protein, and on March 23, 2020 FDA deemed the Egrifta application (022505) to be a biologics license. FDA states that biological products are not eligible for the 503A or 503B compounding exemptions, so compounded tesamorelin sold by telehealth and anti-aging clinics has no lawful basis, and Egrifta WR by prescription is the only lawful product. A clinician may prescribe Egrifta WR off-label, but use for fat loss in people without HIV has only limited trial support.	Not FDA approved and not approved by any other regulator as of the last verification date. Because retatrutide is not a component of an approved drug, has no USP monograph, and is not on the 503A bulks list, it cannot lawfully be compounded by 503A pharmacies or 503B outsourcing facilities. FDA has warned that unapproved GLP-1 class products sold online, including investigational molecules, are not evaluated for safety, quality, or dose. Any product sold as retatrutide outside a clinical trial is unlawful for human use.
WADA	WADA: WADA prohibited	WADA: WADA prohibited
Routes	Subcutaneous injection into the abdomen once daily (Egrifta WR, Egrifta SV), No oral, sublingual, or nasal form is FDA approved or tested in a published trial	Subcutaneous injection once weekly (clinical trials only)
Typical cost	Egrifta WR has no published list price; a retail cash listing put one 28 day kit at about 10,709 USD, and a manufacturer co-pay program helps eligible commercially insured patients with the approved HIV indication. Compounded tesamorelin has no lawful price, because tesamorelin is a biologic and biologics cannot be compounded. Prices checked 2026-09-22.	Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Last verified	Sep 23, 2026	Sep 23, 2026

Has tesamorelin been tested directly against retatrutide?

No published trial has compared tesamorelin and retatrutide directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do tesamorelin and retatrutide cost?

Typical cost of Tesamorelin and Retatrutide
Dimension	Tesamorelin	Retatrutide
Typical cost	$10,709 per month	Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Price detail	Tesamorelin price by channel	Retatrutide price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Which is better for belly fat?

They work differently. Tesamorelin selectively reduces visceral fat inside the abdomen and was approved for that in adults with HIV. Retatrutide reduces total body weight, but it was not tested as a visceral fat drug and is not approved. No trial has compared them. [1] [2] [4]

Does tesamorelin cause weight loss like retatrutide?

No. Tesamorelin's trials measured visceral fat, not body weight, and it did not change fat under the skin. Retatrutide's phase 2 trial measured body weight and found a mean 24.2% loss at the top dose over 48 weeks. [1] [4]

Which one can I get legally?

Tesamorelin, by prescription as Egrifta WR; as a biologic it cannot be compounded. Retatrutide is not approved and cannot be compounded, so the only lawful access is enrolling in a registered clinical trial. [8] [10] [11] [12] [14]

Do both lower liver fat?

Both did in trials of people with fatty liver. Tesamorelin lowered hepatic fat fraction by an absolute 4.1% over 12 months in adults with HIV. Retatrutide lowered liver fat by 82.4% relative to baseline at 24 weeks on the top dose in a 98 person substudy. [3] [5]

Are they allowed in sport?

No. Tesamorelin is prohibited under WADA section S2 and retatrutide under section S0. [13]

Conditions studied

From the blog

Retatrutide benefits beyond weight loss: liver fat, blood sugar, and blood pressure
What retatrutide trials measured besides weight: liver fat, HbA1c, blood pressure, lipids, fat mass, and knee pain. What is proven, what is post hoc, and what is still unknown.
Peptides for weight loss, ranked by human evidence
Tirzepatide, semaglutide, and liraglutide lead on human trials. Retatrutide is trial-only, and AOD-9604 and 5-amino-1MQ are animal-only. Ranking, legal status, and dated prices.
Tesamorelin before and after: what the trials measured
Tesamorelin results from the 26 and 52 week trials: about 15 to 18% less visceral fat, little change in weight, and fat that came back after stopping. Why photos are not trial data.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 23). Tesamorelin vs retatrutide: evidence, cost, and legality. https://peptideagent.ai/compare/tesamorelin-vs-retatrutide
HTML link: <a href="https://peptideagent.ai/compare/tesamorelin-vs-retatrutide">Tesamorelin vs retatrutide: evidence, cost, and legality</a>, PeptideAgent, updated September 23, 2026.

Tesamorelin vs retatrutide

The short answer